You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Kinase inhibitors in the treatment of chronic hepatitis C virus
  1. E Bardou-Jacquet,
  2. R Lorho,
  3. D Guyader
  1. Liver Disease Department, University Hospital Pontchaillou, Rennes, France
  1. Correspondence to E Bardou-Jacquet, Liver Disease Department, University Hospital Pontchaillou 35000 Rennes, France; edouard.bardou-jacquet{at}chu-rennes.fr

https://doi.org/10.1136/gut.2010.212068

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the publication in Gut by Himmelsbach et al1 in which they assessed whether the modulation of c-Raf by sorafenib affects hepatitis C virus (HCV) replication using the in vitro replicon system. The authors showed that sorafenib blocks HCV replication in vitro, by decreasing c-Raf phosphorylation and by affecting the post-translational processing of NS5A, which is required for the replication of the virus. We would like to report here a clinical observation that could suggest the clinical potential interest of kinase pathway inhibitors as a therapeutic option in chronic hepatitis C.

    Erlotinib is a highly selective kinase inhibitor targeting epidermal growth factor receptor (EGFR), the signalling pathway of which includes the Ras/Raf/mitogen-activated protein kinase (MEK)/extracellular-related-signal kinase (ERK) pathway. Erlotinib has been approved in non-small cell lung …

    View Full Text

    Footnotes

    • Linked articles 217323

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles